<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Piperlongumine (PL), a pepper plant <z:chebi fb="13" ids="22315">alkaloid</z:chebi> from Piper longum, kills <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> cells in a highly selective, potent fashion </plain></SENT>
<SENT sid="1" pm="."><plain>To evaluate whether PL may have similar effects on malignant blood cells, we determined the efficacy with which PL inhibits the B-lymphocyte derived <z:hpo ids='HP_0002664'>neoplasm</z:hpo>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Low micromolar concentrations of PL (IC(50) = 2.8 μM × 8.5 μM) curbed growth and survival of two EBV(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines (Daudi, Raji) and two EBV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines (Ramos, DG-75), but left <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood B-lymphocytes unharmed </plain></SENT>
<SENT sid="3" pm="."><plain>PL-dependent cytotoxicity was effected in part by reduced NF-κB and MYC activity, with the former being caused by inhibition of IκBα degradation, nuclear translocation of p65, and binding of NF-κB dimers to cognate DNA sequences in gene promoters </plain></SENT>
<SENT sid="4" pm="."><plain>In 4 of 4 BL cell lines, the NF-κB/MYC-regulated cellular target genes, E2F1 and MYB, were down regulated, while the stress sensor gene, GADD45B, was up regulated </plain></SENT>
<SENT sid="5" pm="."><plain>The EBV-encoded oncogene, LMP-1, was suppressed in Daudi and Raji cells </plain></SENT>
<SENT sid="6" pm="."><plain>Considering that NF-κB, MYC and LMP-1 play a crucial role in the biology of many <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">blood cancers</z:e> including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, our results provide a strong preclinical rationale for considering PL in new intervention approaches for patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>